BSTC - BioSpecifics Technologies Corp.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
64.06
-0.15 (-0.23%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close64.21
Open64.30
Bid61.00 x 1400
Ask65.51 x 800
Day's Range63.50 - 64.30
52 Week Range45.81 - 72.83
Volume40,041
Avg. Volume42,922
Market Cap470.16M
Beta (5Y Monthly)1.31
PE Ratio (TTM)20.21
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    BioSpecifics Reports Third Quarter 2019 Financial and Operating Results

    - 15% year-over-year increase in royalty revenues for XIAFLEX® - BLA filing of XIAFLEX® for treatment of cellulite submitted to FDA in September 2019 LYNBROOK, N.Y. , Nov. 8, 2019 /PRNewswire/ -- BioSpecifics ...

  • PR Newswire

    Jennifer Chao Appointed Chairperson of BioSpecifics Technologies Corp. Board of Directors

    LYNBROOK, N.Y., Oct. 23, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that Jennifer Chao has been appointed chairperson of its board of directors, effective immediately. "Jenn's counsel as chairperson of our board will be instrumental as we seek to unlock new opportunities to generate value for all our stakeholders. BioSpecifics has accomplished significant milestones in the last few years and now, as we usher the company into its next phase of growth, her life sciences industry expertise will bring an elevated level of strategy, execution and focus," said J. Kevin Buchi, chief executive officer of BioSpecifics.

  • PR Newswire

    BioSpecifics Technologies Corp. Names J. Kevin Buchi as Chief Executive Officer

    LYNBROOK, N.Y., Oct. 10, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today named life sciences industry veteran Kevin Buchi chief executive officer of BioSpecifics. "We are extremely pleased to have Kevin join BioSpecifics as chief executive officer. The board of directors believes that Kevin's diversified life sciences leadership experience and business acumen will drive transformative vision and strategy for generating both near- and long-term shareholder value," said Jenn Chao, Chair of the Executive Search Committee.

  • PR Newswire

    BioSpecifics Technologies Corp. Reports Second Quarter 2019 Financial and Operating Results

    - 13% year-over-year increase in royalty revenues for XIAFLEX® - - New data from Phase 1 trial of CCH for treatment of uterine fibroids to be presented at upcoming medical meeting in 2H19 - - Biologics ...

  • PR Newswire

    BioSpecifics Technologies Corp. Announces Authorization of up to $4 Million Stock Repurchase Program

    LYNBROOK, N.Y., May 23, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC) ("BioSpecifics"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that the Executive Committee of its Board of Directors has authorized a stock repurchase program under which BioSpecifics is authorized to repurchase up to $4 million of its outstanding common stock. This decision reflects BioSpecifics' continued confidence in achieving its corporate goals and commitment to increasing value for its stockholders. Pursuant to the repurchase program, BioSpecifics plans to repurchase stock through a broker in the open market, provided that the timing, actual number and price per share of the common stock to be purchased will be subject to market conditions, applicable legal requirements, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended, and various other factors.

  • PR Newswire

    BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2018 Financial Results

    - Positive data from Phase 1 trial of CCH for treatment of uterine fibroids presented at 66th Annual Meeting of the Society for Reproductive Investigation in March 2019 - - 24% year-over-year; 30% quarter-over-quarter ...

  • PR Newswire

    BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman

    LYNBROOK, N.Y., March 18, 2019 /PRNewswire/ -- BioSpecifics Technologies Corp. (BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced with great sadness that Thomas L. Wegman, President of BioSpecifics, passed away on March 13, 2019. Mr. Wegman served as an officer at BioSpecifics for over 20 years and was a member of the Board of Directors since 1994. "It is with great sadness that we report the passing of Tom Wegman.